The Platelet-Activating Factor Receptor’s Association with the Outcome of Ovarian Cancer Patients and Its Experimental Inhibition by Rupatadine
Authors:
- Eileen DeusterEDEileen Deuster
- Ivi HysenajIHIvi Hysenaj
- Maja KahalyMKMaja Kahaly
- Elisa SchmoeckelESElisa Schmoeckel
- Doris MayrDMDoris Mayr
- Susanne BeyerSBSusanne Beyer
- Thomas KolbenTKThomas Kolben
- Anna HesterAHAnna Hester
- Fabian KrausFKFabian Kraus
- Anca Chelariu-RaicuACAnca Chelariu-Raicu
- Alexander BurgesABAlexander Burges
- Sven MahnerSMSven Mahner
Open Access
Abstract
The platelet-activating factor receptor (PAFR) and its ligand (PAF) are important inflammatory mediators that are overexpressed in ovarian cancer. The receptor is an important player in ovarian cancer development. In this study, we aimed to evaluate the prognostic value of PAFR in epithelial ovarian cancer (EOC) and the potential use of its antagonist, rupatadine, as an experimental treatment. Tissue microarrays of ovarian cancer patients, most markedly those with a non-mucinous subtype, immunohistochemically overexpressed PAFR. Elevated cytoplasmic PAFR expression was found to significantly and independently impair patients’ overall and recurrence-free survival (OS: median 83.48 vs. 155.03 months; p = 0.022; RFS: median 164.46 vs. 78.03 months; p = 0.015). In vitro, the serous ovarian cancer subtypes especially displayed an elevated PAFR gene and protein expression. siRNA knockdown of PAFR decreased cell proliferation significantly, thus confirming the receptor’s protumorigenic effect on ovarian cancer cells. The clinically approved PAFR antagonist rupatadine effectively inhibited in vitro cell proliferation and migration of ovarian cancer cells. PAFR is a prognostic marker in ovarian cancer patients and its inhibition through rupatadine may have important therapeutic implications in the therapy of ovarian cancer patients.Keywords
All Related Versions
Funding Information
- “Brigitte & Dr. Konstanze Wegener” foundation (none)
This publication has 40 references indexed in Scilit:
- Glycodelin A is a prognostic marker to predict poor outcome in advanced stage ovarian cancer patientsBMC Research Notes, 2012
- Transcriptional control of melanoma metastasis: The importance of the tumor microenvironmentSeminars in Cancer Biology, 2011
- Accuracy and cut‐off point selection in three‐class classification problems using a generalization of the Youden indexStatistics in Medicine, 2010
- Activated networking of platelet activating factor receptor and FAK/STAT1 induces malignant potential in BRCA1-mutant at-risk ovarian epitheliumReproductive Biology and Endocrinology, 2010
- Wild-Type BRCA1, but not Mutated BRCA1, Regulates the Expression of the Nuclear Form of β-CateninMolecular Cancer Research, 2010
- Safety of Rupatadine Administered Over a Period of 1 Year in the Treatment of Persistent Allergic RhinitisDrug Safety, 2009
- Activation of Platelet-Activating Factor Receptor and Pleiotropic Effects on Tyrosine Phospho-EGFR/Src/FAK/Paxillin in Ovarian CancerCancer Research, 2008
- Emerging Roles of PAR-1 and PAFR in Melanoma MetastasisCancer Microenvironment, 2008
- Growth inhibition and differentiation of human breast cancer cells by the PAFR antagonist WEB-2086British Journal of Cancer, 2006
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001